Iceland vs Mongolia: HIV/AIDS deaths averted by antiretroviral therapy
Iceland
13.85 deaths
in 2024
Mongolia
16.78 deaths
in 2024
Iceland rank
152nd
Mongolia rank
150th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Iceland
- Mongolia
How they compare
Mongolia currently reports 16.78 deaths against 13.85 deaths in Iceland, a difference of 2.93 deaths.
That makes Mongolia's figure about 1.2 times Iceland's.
The two have swapped places 2 times across 35 shared years of data; in 1990 it was Mongolia ahead.
Iceland ranks 152nd and Mongolia ranks 150th of 157 countries.
Across the 4 decades both report, Iceland averaged higher in 2 and Mongolia in 2.
Head to head by decade
| Decade | Iceland | Mongolia | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0.6236 deaths | 0 deaths | 0.6236 deaths | Iceland |
| 2000s | 7.56 deaths | 0.4658 deaths | 7.09 deaths | Iceland |
| 2010s | 10.17 deaths | 11.81 deaths | 1.64 deaths | Mongolia |
| 2020s | 12.92 deaths | 16.38 deaths | 3.46 deaths | Mongolia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Iceland or Mongolia?
- Mongolia, at 16.78 deaths against 13.85 deaths in Iceland as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Iceland and Mongolia?
- 2.93 deaths, with Mongolia ahead.
- How many years of comparable data are there for Iceland and Mongolia?
- 35 years are reported by both, from 1990 to 2024.
- How do Iceland and Mongolia rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Iceland ranks 152nd and Mongolia ranks 150th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.